LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・Bridgebio Pharma Inc
Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

67.29 -0.18

Strong Buy

Prijsupdate 10 jun 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

66.42

Max

69.2

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

75M

-105M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+58.53% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-132M

13B

Vorige openingsprijs

67.47

Vorige sluitingsprijs

67.29

Nieuwssentiment

By Acuity

48%

52%

147 / 344 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Winsten

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Lezen

10 jun 2026, 23:19 UTC

Populaire aandelen

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Lezen

10 jun 2026, 23:09 UTC

Belangrijke Marktbewegers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Lezen

10 jun 2026, 23:04 UTC

Winsten

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Lezen

10 jun 2026, 20:44 UTC

Belangrijke Marktbewegers

Caterpillar Raises Quarterly Dividend 8%

DJ

Lezen

10 jun 2026, 23:49 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Should Take No Options Off The Table

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Lezen

10 jun 2026, 23:48 UTC

Acquisities, Fusies, Overnames

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Lezen

10 jun 2026, 23:47 UTC

Marktinformatie

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Lezen

10 jun 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Lezen

10 jun 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

10 jun 2026, 23:38 UTC

Marktinformatie

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Lezen

10 jun 2026, 23:32 UTC

Marktinformatie

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Lezen

10 jun 2026, 23:20 UTC

Marktinformatie

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Lezen

10 jun 2026, 22:05 UTC

Marktinformatie

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Lezen

10 jun 2026, 21:57 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:52 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:35 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 21:22 UTC

Winsten

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:39 UTC

Marktinformatie
Winsten

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Lezen

10 jun 2026, 20:34 UTC

Winsten

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Winsten

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

DJ

Lezen

10 jun 2026, 20:33 UTC

Marktinformatie
Winsten

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

58.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.29 USD  58.53%

Hoogste 157 USD

Laagste 82 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

17

Buy

2

Hold

0

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

147 / 344 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat